<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268318</url>
  </required_header>
  <id_info>
    <org_study_id>NU359</org_study_id>
    <nct_id>NCT02268318</nct_id>
  </id_info>
  <brief_title>&quot;A Clinical Study for Evaluating the Effect of a Plant Sterol-enriched Fermented Dairy Product on Blood Lipoprotein Profile in Japanese Adults&quot;</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE EFFECT OF A 12-WEEK CONSUMPTION PERIOD OF SINGLE DOSE A DAY OF A PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT ON BLOOD LIPOPROTEIN PROFILE IN JAPANESE ADULTS WITH HIGH LDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Japan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INVESTIGATE THE EFFECT OF A 12-WEEK CONSUMPTION PERIOD OF SINGLE DOSE A DAY OF A PLANT
      STEROLS-ENRICHED FERMENTED DAIRY PRODUCT ON BLOOD LIPOPROTEIN PROFILE IN JAPANESE ADULTS WITH
      HIGH LDL-C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of LDL-cholesterol concentration after 6 weeks of product consumption, expressed as a relative change from baseline.</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Evolution of LDL-cholesterol concentration after 6 weeks of product consumption, expressed as a raw change from baseline. - Evolution of LDL-cholesterol concentration after 3 and 12 weeks of product consumption, expressed as a relative and raw changes</measure>
    <time_frame>baseline, 3 / 6 / 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Subjects With High LDL-Cholesterol</condition>
  <arm_group>
    <arm_group_label>1-Fermented Dairy Product with Phytosterols (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Fermented dairy Product with No Phytosterols (control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one arm control product= 1 bottle of dairy product/day with no Phytosterols</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1-Fermented Dairy Product with Phytosterols (test)</intervention_name>
    <description>1- 1 bottle of test product/day</description>
    <arm_group_label>1-Fermented Dairy Product with Phytosterols (test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2-Fermented dairy Product with No Phytosterols (control)</intervention_name>
    <description>2-1 bottle of control product/day</description>
    <arm_group_label>2-Fermented dairy Product with No Phytosterols (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An individual must fulfil all of the following criteria in order to be eligible for
             trial enrolment

        To be checked at the inclusion visit (V1):

          -  II 01: Male/female subject, aged from 20 to 75 years (bounds included).

          -  II 02: Subject with body mass index (BMI) between 18.5 kg/m2 (bound included) and 30
             kg/m2 (bound excluded).

          -  II 03: Subject with LDL-cholesterol blood level between 120 mg/dL (3.1 mmol/L) and 160
             mg/dL (4.14 mmol/L) (bounds included).

          -  II 04: Subject with triglycerides under 200 mg/dL (2.3 mmol/L).

          -  II 05: Non hypertensive subject defined with Systolic Blood Pressure (SBP) &lt;140 mmHg
             and Diastolic Blood Pressure (DBP) &lt;90 mmHg OR subject with treated and controlled
             hypertension defined with SBP &lt;140 mmHg and DBP &lt;90 mmHg since at least 1 month.

          -  II 06: Subject who already received the dietary recommendations advisable for hyper or
             borderline hyper-LDL cholesterolemic subjects (according to Japan Atherosclerosis
             Society guidelines).

          -  II 07: Subject agreeing not to consume any supplements/ food products enriched with
             plant sterols and plant stanols in any form and soy milk product during the study
             period.

          -  II 08: Female subject must be postmenopausal for at least 12 months prior to trial
             entry or surgically sterile (i.e. hysterectomy, bilateral oophorectomy or bilateral
             tubal ligation) OR if of child bearing potential, female subject must be using or
             complying with one of the following medically approved methods of contraception such
             as, but not exclusively:

          -  Oral birth control pills (at least 1 full monthly cycle prior to study product
             administration);

          -  Intra-uterine device (IUD);

          -  Double barrier methods (such as condoms and spermicide);

          -  Abstinence, when in the opinion of the investigator, their occupation or life style
             gives efficient evidence that abstinence will be maintained throughout the study and
             for one month thereafter.

          -  II 09: Subject covered by social security or covered by similar system.

          -  II 10: Subject, upon briefing of the content of the present study, fully understanding
             and agreeing to its objective; and being able to personally sign a written informed
             consent.

          -  II 11: Subject having given written (dated and signed) inform consent to take part in
             the study.

          -  II 12: Asian subjects originating from Japan.

          -  II 13: Subject who is able to communicate well with the investigator and to comply
             with the requirements of the entire study.

          -  II 14: Subject having a fridge at home for study products storage with sufficient
             capacity.

        To be checked at the randomization visit (V2):

          -  RI 01: Subject with LDL-cholesterol blood level between 120 mg/dL (3.1 mmol/L) and 160
             mg/dL (4.14 mmol/L) (bounds included).

          -  RI 02: Subject with triglycerides under 200 mg/dL (2.3 mmol/L).

          -  RI 03: Subject having compliance to the product during the run-in period 80%.

          -  RI 04: Subject having followed the dietary recommendations advisable for
             hypercholesterolaemic patients.

        Exclusion Criteria:

          -  An individual fulfilling any of the following criteria is to be excluded from trial
             enrolment

        To be checked at the inclusion visit (V1):

          -  IE 01: Subject under hypocholesterolaemic treatment.

          -  IE 02: Subjects having stopped taking their hypocholesterolemic drugs or products
             (statins, ezetimibe, sequesterants, niacin, nicotinates, probucol, omega-3 fatty acids
             (EPA-DHA, ALAâ€¦), and fibrates) less than 3 months ago.

          -  IE 03: Subject with known allergy or hypersensitivity to plant sterols and to any
             component of the study product (milk protein for example).

          -  IE 04: Subjects having sitosterolemia.

          -  IE 05: Subject having experienced any cardiovascular event (cardiac infarction, angina
             attack, surgical or endoscopic coronary angioplasty, stroke, arterial disease, etc.).

          -  IE 06: Subject suffering from any serious or chronic liver, renal, cardiovascular,
             respiratory, endocrine or metabolic disorders.

          -  IE 07: Subject with gastro-intestinal disorders (such as diarrhoea, constipation,
             irritable bowel syndrome) or using laxatives.

          -  IE 08: Subject with diabetes Type I and Type II or Fasting Blood Sugar test (FBS) &gt;
             125 mg/dL (7.0 mmol/L) at screening visit.

          -  IE 09: Subject who had any surgery or intervention requiring a general anesthesia in
             the preceding 4 weeks, or who plans to have one during the course of the study.

          -  IE 10: Subject receiving (currently or in the 4 last weeks) systemic treatment or
             topical treatment likely to interfere with evaluation of the study parameters.

          -  IE 11: Subject involved in any other clinical study within the preceding month or in
             the exclusion period after another clinical study.

          -  IE 12: Subject having blood sample of 200 mL or more taken (e.g., donated blood)
             within 1 month, or 400 mL or more within 3 months before the start of the present
             study.

          -  IE 13: Subject with heavy alcohol intake (&gt; 60 g/day).

          -  IE 14: Subject taking any treatment for anorexia, weight loss, or any form of
             treatment likely to interfere with metabolism or dietary habits (e.g. hypolipemic,
             hypoglycaemic treatments).

          -  IE 15: For female subject: pregnant woman or woman planning to become pregnant during
             the study; breast-feeding woman.

          -  IE 16: For female subject: subject likely to change her contraceptive method or
             hormone replacement therapy during the study.

          -  IE 17: Subject in a situation, which in the investigator's opinion could interfere
             with optimal participation in the present study (e.g. non-dairy-products consumer) or
             could constitute a special risk for the subject.

          -  IE 18: Subject who is susceptible to not comply with dietary qualitative restriction
             during the study period.

          -  IE 19: Vulnerable subjects defined as individuals whose willingness to volunteer in
             the clinical trial may be unduly influenced by the expectation, whether justified or
             not, of benefits associated with participation, or of a retaliatory response from
             senior members of a hierarchy in case of refusal to participate. Examples are members
             of a group with a hierarchical structure, such as medical, pharmacy, dental and
             nursing students, subordinate hospital and laboratory personnel, employees of the
             pharmaceutical industry, members of the armed forces, and persons kept in detention.

          -  IE 20: Subjects with known lactose intolerance or known allergy to plant sterols.

          -  IE 21: Subjects being a heavy soybean milk consumer.

          -  IE 22: Subject expected to be living in the same home as a current participating
             subject and to concomitantly receive some study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine MRINI, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Danone Research Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yaesu Sakura-dori Clinic</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Subjects, High LDL-C, fermented-dairy products, phytosterols</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

